– Total revenues remain strong at CHF 7.2 billion (CHF 7.3 billion in 2023)
– Record CHF 833 million raised by privately funded companies drives 22% overall rise in capital investment to CHF 2.5 billion (CHF 2.0 billion in 2023)
    Alentis Therapeutics (CHF 163 million) and SixPeaks Bio (CHF 102 mil…

– Record revenues of CHF 7.3 billion (USD 8.1 billion)
– Capital investments increase by more than 50% to CHF 2 billion – CHF 1.4 billion by public companies, CHF 0.6 billion by private companies
– Significant licensing and M&A activity in 2023 – VectivBio, T3, Vertex, Santhera
– R&D investments of pu…

Die Schweiz gehört zu den attraktivsten Standorten für Biotech-Unternehmen und profitiert von einem anhaltend hohen Kapitalzufluss. Gleichzeitig hat die Schweiz gute Voraussetzungen, ihre starke Position in der Herstellung komplexer Biopharmazeutika weiter auszubauen, wie der wichtigste Biotech-Ko…

- Capital investments in Swiss biotech companies almost tripled from 2019 to 2020 reaching CHF 3.4B (USD 3.7B)
- R&D investments increased by 10% to CHF 2.2B (USD 2.3B)
- The number of employees in Swiss R&D biotech companies increased by 8% to 16,300
- High quality patent output helped maintain Switze…

Since 2018, the Swiss Biotech Association has been honoring outstanding achievements with the Swiss Biotech Success Stories Awards. Innovative companies, entrepreneurs and scientists are recognized by the industry association for their significant successes and lasting contributions to the Swiss bio…

- 2019 wurden 1,2 Milliarden Franken in private und öffentliche Biotech-Unternehmen investiert
- Gentherapie, künstliche Intelligenz und die Herstellung fortgeschrittener Biologika entwickelten sich zu ergänzenden Stärken
- Lizenzgeschäfte und Kooperationen steigerten die Einnahmen
- Das Schweizer Biotech-Ã…

The Swiss biotech industry continues to be buoyant and once again managed to increase its sales, exports and research investments in 2018. As a result, it is laying the foundations for further growth and forward-looking development. Capital investment in listed biotech companies saw an especially st…

The Swiss biotech industry has reached record figures for 2017 in financing, infrastructure investment, and exports. This shows that confidence in its ability to create value and innovate remains unshaken. The most prominent example is the acquisition of Actelion by Johnson & Johnson, which, at…

On the occasion of its 20th anniversary, the Swiss Biotech Association launches Swiss Biotech Success Stories in recognition of the industry’s many accomplishments. Swiss Biotech Success Stories will grow over time to encompass all of the industry’s different facets. An independent jury of exper…